$10.58
1.44% today
Nasdaq, Jun 26, 04:16 pm CET
ISIN
US1266381052
Symbol
CVRX

CVRx Inc Share price

$10.43
+2.98 40.00% 1M
-14.56 58.26% 6M
-21.01 66.83% YTD
-3.96 27.52% 1Y
-17.57 62.75% 3Y
-17.57 62.75% 5Y
-17.57 62.75% 10Y
Nasdaq, Closing price Tue, Jun 25 2024
ISIN
US1266381052
Symbol
CVRX
Sector

Key figures

Market capitalization $225.24m
Enterprise Value $175.72m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.17
P/S ratio (TTM) P/S ratio 5.35
P/B ratio (TTM) P/B ratio 3.40
Sales growth (TTM) Sales growth 59.59%
Turnover (TTM) Turnover $42.09m
EBIT (operating result TTM) EBIT $-53.17m
Free cash flow (TTM) Free cash flow $-40.94m
Cash position $80.12m
EPS (TTM) EPS $-2.48
P/E ratio expected negative
P/S ratio expected 4.43
EV/Sales expected 3.46
Short interest 6.67%
Show more

Is CVRx Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.

CVRx Inc Share analysis

Unlock scores for free

Analyst opinions

6 Analysts have issued a CVRx Inc forecast:

4x Buy
67%
2x Hold
33%

Analyst opinions

6 Analysts have issued a CVRx Inc forecast:

Buy
67%
Hold
33%

Financial data from CVRx Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
42 42
60% 60%
100%
- Direct costs 7.07 7.07
21% 21%
17%
35 35
71% 71%
83%
- Selling and administrative expenses 76 76
42% 42%
181%
- Research and development costs 11 11
1% 1%
27%
-53 -53
19% 19%
-125%
- Depreciation and amortization 0.52 0.52
8% 8%
1%
EBIT (operating result) EBIT -53 -53
19% 19%
-126%
Net profit -52 -52
21% 21%
-124%

Figures in millions USD.

Don't miss a thing! We will send you all news about the CVRx Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

CVRx Inc Share News

Neutral
GlobeNewsWire
one day ago
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and estab...
Neutral
Accesswire
17 days ago
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
19 days ago
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
More CVRx Inc News

Company profile

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kevin Hykes
Employees 200
Founded 2001
Website www.cvrx.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now